Research design

Guardian Research Network and Cytel announce presentation at ISPOR 2022 detailing impact of Covid-19 on breast cancer

Joint efforts recognize the impact of the global pandemic on the staging of cancer cases in United States at the conference of the International Society for Pharmacoeconomics and Outcomes Research

SPARTANBURG, SC, April 27, 2022 /PRNewswire/ — Guardian Research Network, Inc. (GRN) and Cytel Inc. are pleased to announce an upcoming presentation at ISPOR 2022, washington d.c.. ISPOR is the leading professional society for health economics and outcomes research. The session, titled “Studies on the impacts of COVID-19 on health care” will detail several studies, including “Evaluating the impact of COVID-19 on the diagnosis and staging of incident breast cancer cases: a retrospective analysis of medical record data from United States“, scheduled for 10 a.m. ET, Wednesday, May 18, 2022.

To be delivered by Rachel Kapp, research consultant, Cytel Inc., the specific study is a retrospective analysis of electronic medical record data provided by GRN. Other authors of the study are Charles S. Hurmiz, Brant Bonnerand Andrea McCracken of the GRN, and Fräence Hardtstock and Thomas Wilker from Cytel.

“This study demonstrates significant impacts on breast cancer diagnostic delay and differences in the distribution of metastatic stages,” said Hurmiz, Chief Information Officer and Acting Director of Data Science at GRN. “We are excited to work with Cytel to use GRN’s millions of real-world cancer records to translate Covid-19 data into breast cancer treatment information. We believe this information will be valuable to physicians, thought leaders, and health outcomes experts. , which will use this data to better care for breast cancer patients, especially those cared for in our community health systems.”

Thomas Wilkersenior scientist at Cytel, observed “While the initial urgency of the pandemic appears to have subsided, much work remains to be done to examine the longer-term impact, particularly on people with co-morbidities. Our collaboration with Guardian shows how real-world solutions can be channeled to ensure the impact of the pandemic on vulnerable patients is accurately represented.”

The study presentation will take participants through the assessment of the impact of the pandemic on breast cancer staging in the United States. Adult patients diagnosed with breast cancer 01/01/2018 to 31/12/2020 were included to understand the number of new diagnoses of cancer and tumor metastasis, based on a triangulation of TNM measurements, physician staging assessments, and diagnosis codes associated with metastatic disease recorded during a specific quarter.

To learn more about the conference and how to register to hear the presentation, visit ISPOR, Improving Healthcare Decisions.

About the Guardian Research Network
Guardian Research Network, a not-for-profit organization, is a national healthcare system consortium focused on advancing technology to accelerate the cure of life-threatening diseases such as cancer. GRN works with life science customers and healthcare system partners to increase participation in data-driven clinical trials, optimize therapeutic and diagnostic studies, and use real-world data to improve patient access to precision medicines in underserved communities. To learn more about this 501(c)(3), visit

About Cytel Inc.
Cytel is the leading provider of statistical software and advanced analytics for the design and execution of clinical trials. For more than thirty years, Cytel’s scientific rigor and operational excellence have enabled biotech and pharmaceutical companies to navigate uncertainty, prove their worth and make evidence-based decisions. Its experts offer state-of-the-art software, data-driven analysis, hard evidence and strategic advice. Based at Waltham, MACytel has over 1,500 employees across North America, Europeand Asia. For more information about Cytel, visit us at

GRN media contact
Charlene Smith-McCawMBA
Guardian Research Network
Mobile: 610-888-9024
[email protected]

Media contact at Cytel
Esha Senchaudhuri, PhD
Cytel Inc.
Office: 617-987-9402
[email protected]

SOURCE Guardian Research Network